NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers
Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentReceived third-party recognition of INB-619 in a Nature Reviews Drug
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune
Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers
Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and
Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB) ("IN8bio" or the "Company"), a clinical-stage biopharmaceutical company developing innovative gamma-delta ("γδ") T cell therapies for cancer and
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today
